Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis

Table 3 Proportion of patients experiencing a clinically meaningful change in health status with salmeterol or placebo/usual therapy.

Time period	Salmeterol		Placebo		Pooled estimate of difference
	No. of subjects	% with meaningful change	No. of subjects	% with meaningful change	Difference in % meaningful change	95% CI	P value
Intent to treat population
Weeks 8–28	1150	45.3%	1129	37.9%	7.7%	4.6, 10.7	<0.0001
Weeks 8–52	1156	45.9%	1131	37.9%	7.9%	5.1, 10.7	<0.0001
Poorly reversible population
Weeks 8–28	934	44.6%	935	38.9%	5.4%	2.1, 8.8	0.0016
Weeks 8–52	939	45.3%	937	39.0%	5.9%	2.8, 8.9	0.0002

ISSN: 1465-993X